February 21, 2011 (San Diego, California) — A low dose of the synthetic antifibronolytic agent tranexamic acid (TA) decreases the amount of blood loss and the need for blood transfusions during ...

Please provide your email address to receive an email when new articles are posted on . Compared with placebo, tranexamic acid was linked with reduced perioperative blood loss and transfusions for ...

Tranexamic acid (TXA) failed to reduce the need for red blood cell (RBC) transfusion following surgery for liver cancer, including colorectal liver metastases, the placebo-controlled HeLiX trial ...

Please provide your email address to receive an email when new articles are posted on . Tranexamic acid may be indicated for the prevention of heterotopic ossification. Patients undergoing surgery for ...

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO) – a common ...

Local injection of tranexamic acid (TXA) effectively reduced the risk for clinically significant bleeding following Mohs micrographic surgery (MMS), results from a single-center cohort study showed.

Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...

A breakthrough could be coming in the way young people recover from surgery to reconstruct the anterior cruciate ligament (ACL) in the knee, a common sports injury. A new clinical trial soon will ...

Tranexamic acid is an antifibrinolytic drug that reduces bleeding in patients undergoing cesarean section or cardiac surgery. In this randomized trial involving patients undergoing noncardiac surgery, ...

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO)—a common ...